GLP-1 & Incretin Science
An Amylin Analogue Built to Stand Alone
Petrelintide is a long-acting amylin analogue. Fischer Munch and colleagues published its development in the Journal of Medicinal Chemistry in November 2025 under the description of a potent, stable, long-acting human amylin analogue.
Key facts
- Class
- Long-acting amylin analogue
- Described as
- Potent, stable, long-acting, human
- Development paper
- Fischer Munch 2025 (PMID 41217931)
- Journal
- J Med Chem, 27 November 2025
- Developers
- Zealand Pharma with Boehringer Ingelheim
- Amylin's role
- Satiety signal released after eating
- Authorisation
- None
What amylin does
The paper's own framing describes amylin as a physiological satiety signal released after nutrient intake, which makes it an attractive pharmacological target for weight management. It is co-secreted with insulin from pancreatic beta cells and signals fullness through routes distinct from the incretins.
Why a separate pathway is worth pursuing
Because it is not the incretin pathway. Every compound engaging GLP-1, GIP or glucagon is working within one hormonal system. Amylin signals satiety through different receptors, so it offers a mechanism that could add to incretin effects rather than overlapping with them — which is the rationale behind pairing them in CagriSema.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
Why the word human in the title matters
Human amylin aggregates into amyloid fibrils, which is what made the native peptide undeliverable as a medicine and why pramlintide substitutes three residues with prolines borrowed from rat amylin. Describing a compound as a stable human amylin analogue is a claim about having solved that problem within the human sequence rather than by importing rodent residues.
Why long-acting is the other engineering achievement
Native amylin has a very short half-life, and pramlintide requires administration with meals. Extending duration to allow infrequent dosing is a separate problem from preventing aggregation, and solving both in one molecule is what a development paper in a medicinal chemistry journal is reporting.
Why the timing is interesting
REDEFINE 4 showed CagriSema, which pairs an amylin analogue with semaglutide, failing to demonstrate non-inferiority against tirzepatide. That result concerns one combination at one dose pair and says nothing about amylin as a target on its own — which a standalone amylin analogue is positioned to address directly.
Regulatory position
Petrelintide holds no marketing authorisation anywhere and is investigational. Nothing supplied on this site is related to it, and no research material is an amylin analogue or an alternative to any licensed medicine.
Extended research context
The GLP-1 & Incretin Science deep dive
Deep dive: the two routes to a bigger effect
Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.
Deep dive: why a percentage is not a result
The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.
Deep dive: what happens after the trial stops
Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.
Research applications
- ▸Comparing incretin and amylin compounds on a like-for-like basis
- ▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
- ▸Tracking the obesity pipeline across sponsors and jurisdictions
- ▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
- ▸Distinguishing licensed medicines from investigational compounds
Handling checklist
- ✓Identify which estimand a quoted percentage comes from before citing it
- ✓Check the trial population and baseline BMI against the comparison you are making
- ✓Confirm the duration and whether the reduction curve had plateaued
- ✓Read discontinuation rates alongside efficacy figures
- ✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Comparing headline percentages across different trials
Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.
✗ Quoting the larger of two figures from the same trial
Fix: Name the estimand. Efficacy and treatment-policy answer different questions.
✗ Treating peak reduction as a durable outcome
Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.
✗ Assuming an oral route means a weaker mechanism
Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.
✗ Reading investigational compounds as available treatments
Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Which weight-loss compound produces the largest reduction?
- What is the difference between CagriSema and amycretin?
- What is an amylin receptor agonist?
- How much weight is regained after stopping a GLP-1?
- Why does CagriSema report two different percentages?
- Why is orforglipron less effective than retatrutide?
Frequently asked questions
- What is amylin?
- A satiety signal co-secreted with insulin after nutrient intake, signalling fullness through routes distinct from the incretins.
- Why does 'human' amylin analogue matter?
- Human amylin aggregates into amyloid fibrils. Pramlintide avoided that by borrowing rat prolines; a stable human analogue solves it within the human sequence.
- Why develop amylin on its own?
- REDEFINE 4 tested one amylin-plus-GLP-1 combination, not amylin as a target. A standalone analogue addresses that question directly.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedFischer Munch H et al., Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue — J Med Chem 2025 (PMID 41217931)pubmed.ncbi.nlm.nih.gov
- PubMedBailey CJ, Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes — Peptides 2026 (PMID 41747885)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268) — Maintenance of weight reductionclinicaltrials.gov
- RefNovo Nordisk · CagriSema REDEFINE 1, published in NEJMprnewswire.com
- PubMedAmycretin phase 1b/2a subcutaneous study — PubMed (PMID 40550231)pubmed.ncbi.nlm.nih.gov
- RefTrajectory of weight regain after GLP-1 cessation — eClinicalMedicinethelancet.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- EMAICH E9(R1) — estimands in clinical trials (EMA)ema.europa.eu
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More GLP-1 & Incretin Science articles
- The Amyloid Problem at the Centre of Amylin DesignHuman amylin forms amyloid fibrils. Every amylin medicine is a solution to that, and the two available solutions are instructively different.
- The Class's Defining Safety PropertyGLP-1 amplifies insulin secretion only when glucose is already elevated. Below that threshold the signal does almost nothing — which is the whole point.
- Forcing the Channel Shut Regardless of GlucoseSulfonylureas close the beta cell's potassium channel directly, bypassing the glucose sensing step. That is precisely why they cause hypoglycaemia.
- The Number Depends on Three Things Before the DrugBackground therapy, the glucose threshold used, and how much HbA1c fell all move a hypoglycaemia figure. The compound is often the smallest factor.
- What the Class Reliably ProducesGastrointestinal effects dominate and follow from the mechanism. A 2014 review set out the profile before the current generation existed.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchRetatrutide Molecular Structure and Properties
- GHK-Cu (Copper Peptide)GHK-Cu Mechanism: What Is Actually Proposed
- TB-500 (Thymosin β4 fragment)How Actin Sequestration Works
- BPC-157 (Pentadecapeptide)BPC-157 Structure and Sequence
- CJC-1295 & IpamorelinIpamorelin Sequence and Chemical Identity
- Peptide ReferenceLyophilisation: Why Peptides Arrive as Powder
- Bacteriostatic WaterWhat Is Bacteriostatic Water?
- Research & Regulatory NewsAre Research Peptides Legal in the UK?
- MOTS-c (Mitochondrial Peptide)MOTS-c CAS Number and Chemical Identity
- Semax (ACTH Fragment Peptide)Semax Regulatory Status: Registered Where, and Why It Matters
- Selank (Tuftsin Analogue)Selank CAS Number and Chemical Identity
- DSIP (Delta Sleep-Inducing Peptide)DSIP CAS Number and Chemical Identity
- KLOW (Blend)Four Identities, Four Masses, One Vial
- GLOW (Blend)One Volume, Three Peptides
- MT-2 (Melanotan II)What an Approved Melanocortin Agonist Looks Like
- IGF-1 LR3IGF-1 LR3 Storage: A Folded Protein, Not a Peptide
- GlutathioneGlutathione and Skin Research
- NAD+What the Human Trials Actually Found
- KPVFragment Logic: KPV Against Its Parent